Thursday, 18 October, 2018

AstraZeneca plc 2.8% Potential Upside Indicated by Liberum Capital

Syndicate Post image AstraZeneca plc 2.8% Potential Upside Indicated by Liberum Capital
Nellie Chapman | 04 February, 2018, 12:37

Several other analysts also recently issued reports on AZN. Sanford C. Bernstein set a GBX 5,780 ($81.17) price objective on AstraZeneca and gave the stock a "buy" rating in a report on Monday, September 25th. Deutsche Bank reissued a "buy" rating and set a GBX 5,600 ($78.64) price target on shares of AstraZeneca in a research note on Wednesday, October 11th. BNP Paribas set a GBX 5,800 ($81.45) price objective on AstraZeneca and gave the stock a "buy" rating in a report on Monday, September 25th.

Heading into the earnings release, covering sell-side analysts have a consensus target price of $39.45 on AstraZeneca PLC shares.

In taking a look at technical levels, AstraZeneca PLC (NYSE:AZN) shares are trading 4.68% away from the 50 day simple moving average and 8.45% away from the 200 day simple moving average. The firm has a market cap of $88,990.01, a PE ratio of 12.87, a PEG ratio of 2.72 and a beta of 0.70. After a recent check, company stock has been trading near the $35.14 mark.

Total revenue increased 3 percent to $5.78 billion from last year's $5.59 billion.

Fourth-quarter profits came in better than analysts had expected, helped by one-off tax gains and growing revenue. FTB Advisors Inc. boosted its stake in AstraZeneca by 3.2% in the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company's stock valued at $127,000 after purchasing an additional 984 shares during the period. In looking at volatility levels, the shares saw weekly volatility of 1.54% and 1.06% over the past month.

ILLEGAL ACTIVITY NOTICE: "AstraZeneca (NYSE:AZN) Given a $38.00 Price Target at BMO Capital Markets" was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this news story on another site, it was copied illegally and reposted in violation of USA and worldwide trademark and copyright law.

As of writing, AstraZeneca PLC's RSI stands at 58.81. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold.